Capsules (e.g., Of Gelatin, Of Chocolate, Etc.) Patents (Class 424/451)
  • Patent number: 10314868
    Abstract: Suppository compositions are provided combining a pharmaceutically acceptable matrix material that is solid outside of the human body and in a dry environment, but which melts at body temperature; and apple cider vinegar and one or more species of probiotic bacteria dispersed within the matrix material; wherein the matrix material contains a mixture of fatty acids that are solid at room temperature. Methods for supplementing and nourishing the microbiome of the rectum of a male or female and the microbiome of the vagina of a female are also disclosed. Oral dosage forms of the compositions of the present invention are also provided.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: June 11, 2019
    Inventor: Deborah L. Lynch
  • Patent number: 10314812
    Abstract: The present invention is directed to compositions comprising physiologically active phenolic compounds and methods for making and using the same. In particular embodiments, the compositions described herein include suspension formulations including a physiologically active phenolic compound provided as a nanoparticulate material and dispersed within an edible lipid.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: June 11, 2019
    Assignee: Humanetics Corporation
    Inventors: David C. Egberg, Michael D. Kaytor, John C. Dykstra
  • Patent number: 10307579
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: June 4, 2019
    Assignee: Rani Therapeutics, LLC
    Inventor: Mir Imran
  • Patent number: 10307385
    Abstract: A gelling formulation containing ketamine or a pharmaceutically acceptable salt thereof in water, a poloxamer and one or more pharmaceutically acceptable mucoadhesive agents is provided. Also provided is a method of using the formulation for pain treatment.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: June 4, 2019
    Assignee: Assistance Publique-Hopitaux de Paris
    Inventors: Vincent Boudy, Annick Tibi, Benoît D'Hayer, Marie-Caroline Husson, Sandrine Graff De Faget
  • Patent number: 10300020
    Abstract: The present invention relates to a pharmaceutical calcium acetate formulation and a process for making the same. In particular, the present invention relates to a calcium acetate capsule formulation comprising granules comprising calcium acetate along with other formulation adjuvants contained within a pharmaceutically acceptable capsule.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: May 28, 2019
    Assignee: WEST-WARD PHARMACEUTICALS INTERNATIONAL LIMITED
    Inventors: Julie Economou, Shehla Uraizee
  • Patent number: 10302660
    Abstract: Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders, related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: May 28, 2019
    Assignees: OPKO RENAL, LLC, OPKO IRELAND GLOBAL HOLDINGS, LTD.
    Inventors: P. Martin Petkovich, Christian F. Helvig, Joel Z. Melnick
  • Patent number: 10294019
    Abstract: A system for brewing medicinal beverages, using a cartridge-based beverage formation apparatus, comprises a cartridge containing a beverage composition comprising a mixture of one or more water-soluble active pharmacological treatment agents, such as pain relievers, cold medications, sleeping aids, laxatives, stimulants, or vitamins, and one or more water-soluble non-pharmacological constituents, which can include water-soluble carbohydrates, proteins, alcohols, sweetening, flavoring and coloring agents, anti-caking agents, buffering and acidifying agents, surfactants, thickening and stabilizing agents, antioxidants and/or preservatives.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: May 21, 2019
    Assignee: Raritan Pharmaceuticals Inc.
    Inventor: Vin Nayak
  • Patent number: 10294337
    Abstract: A process for preparing poly(lactide-co-glycolide) copolymer particles with an average particle size in the range of 50-800 nm includes transferring a mixture of poly(lactide-co-glycolide) copolymer, ethanol and carbon dioxide from a first reactor into a second reactor under rapid reduction of the pressure and expansion with phase separation into a gas phase, an ethanol aerosol and an ethanolic suspension containing poly(lactide-co-glycolide) copolymer particles, removing the carbon dioxide gas and the ethanol aerosol from the second reactor, and obtaining the poly(glycolide-co-lactide) copolymer particles in the form of an ethanolic suspension or in dry form from the second reactor.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: May 21, 2019
    Assignee: Evonik Röhm GmbH
    Inventors: Andreas Kirchner, Rosario Lizio, Markus Rolf Rossmeissl, Wolfgang Luley, Johannes Vorholz, Silko Grimm, Marc Schneider
  • Patent number: 10292939
    Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: May 21, 2019
    Assignee: Purdue Pharma L.P.
    Inventors: Ricardo Alberto Vargas Rincon, Joseph Reiz
  • Patent number: 10287401
    Abstract: The present disclosure is directed to polymer and polymer conjugate-based nanoparticle delivery systems for delivering biological agents, and methods of making and using these compositions. Certain embodiments of the present disclosure provide polymers comprising alternating charged and uncharged segments comprising one or more of the following structural units of Formula (I) or Formula (II) or Formula (III): wherein is an uncharged segment comprising polyalkylene glycol; and B is a cationically charged segment comprising at least one polyhydroxy linkage.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: May 14, 2019
    Assignee: California Institute of Technology
    Inventors: Mark E. Davis, Dorothy Pan
  • Patent number: 10272164
    Abstract: Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: April 30, 2019
    Assignee: Incept, LLC
    Inventors: Patrick Campbell, Amarpreet S. Sawhney
  • Patent number: 10272046
    Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: April 30, 2019
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Eleni Dokou, Shahla Jamzad, John P. Caesar, Jr., Majed Fawaz, Laura Das, Chong-Hui Gu, Patricia Nell Hurter, Meghna Jai Israni, Meghan M. Johnston, Dragutin Knezic, Andrew G. Kuzmission, HongRen Wang
  • Patent number: 10265308
    Abstract: The present invention provides a simple and improved dosage form that provides a controlled release of methylphenidate contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to methylphenidate. The dosage form exhibits improved resistance to alcohol-related dose dumping.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: April 23, 2019
    Assignee: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: Hernan D. Benedetti, Cristian R. Franco, Guido S. Bigatti, Joaquina Faour, Ana C. Pastini
  • Patent number: 10258575
    Abstract: The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: April 16, 2019
    Assignee: Triastek, Inc.
    Inventor: Xiaoling Li
  • Patent number: 10251955
    Abstract: A heparin-mimicking sulfonated reverse thermal gel (SRTG) as a heparin-binding therapeutic protein delivery system. This system is designed to turn from low viscous liquid to a physical gel by exposure to body temperature alone. This allows direct deployment through a small gauge needle or catheter at target area with minimal surgical intervention. A unique aspect of this system is that it possesses a net negative charge due to the presence of sulfonate groups. This allows the SRTG to mimic heparin function, binding and preserving the bioactivity of positively charged therapeutic proteins, providing localized and sustained release of such proteins.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: April 9, 2019
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Daewon Park, Brisa Pena-Castellanos
  • Patent number: 10245228
    Abstract: Compositions, systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject for treatment of pain using a device are disclosed.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: April 2, 2019
    Assignee: AcelRx Pharmaceuticals, Inc.
    Inventors: Pamela Palmer, Thomas Schreck, Stelios Tzannis, Larry Hamel, Andrew I. Poutiatine
  • Patent number: 10238712
    Abstract: This invention provides novel peptides and methods to prevent, control, and treat an inflammation, cancer and other disorders, particularly of the gastrointestinal tract and the lung by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound selected from i) 5-aminosalicyclic acid (5-ASA) or a derivative or a pharmaceutically acceptable salt thereof; ii) mercaptopurine; or iii) an anti-TNF therapy.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: March 26, 2019
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventor: Kunwar Shailubhai
  • Patent number: 10231931
    Abstract: Novel thyroid hormone oral dosage forms and methods of making and using the thyroid hormone oral dosage forms are disclosed.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: March 19, 2019
    Assignee: GENUS LIFESCIENCES INC.
    Inventors: Shivaji Phadke, Vaishnavi Parikh
  • Patent number: 10226536
    Abstract: A composition includes a polysaccharide at least one retinoid linked to at least one monosaccharide subunit of the polysaccharide with a covalent linkage. The linkage being degradable by hydrolysis during digestion of the composition to provide controlled, delayed, and/or sustained delivery of the at least one retinoid upon enteral administration of the composition to a subject.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: March 12, 2019
    Assignee: Case Western Reserve University
    Inventors: Songqi Gao, Krzysztof Palczewski, Zheng-Rong Lu
  • Patent number: 10220017
    Abstract: The invention relates to novel liquid pharmaceutical compositions comprising at least one SGLT-2 inhibitor and one or more polar organic solvents, wherein the at least one SGLT-2 inhibitor comprises 1-cyano-2-(4-cyclopropyl-benzyl)-4-(?-D-glucopyranos-1-yl)-benzene according to formula (I): as well as corresponding processes of manufacturing such liquid pharmaceutical compositions and their medical uses.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: March 5, 2019
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Claudius Weiler, Thomas Duch, Marbod Haase, Timothy Shane Priddy, Heike Stettler
  • Patent number: 10213451
    Abstract: This invention provides methods, processes, compounds and compositions for modulating the gene expression or secretion of adhesion proteins, angiopoietins or their receptors to cure diseases, for anti-angiogenesis and for treating parasites, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, myosin, vitronectin, collagen, laminin, glycosylation cell surface proteins, polyglycans, cadherin, heparin, tenascin, CD 54, CAM, elastin and FAK; wherein the angiopoietins comprise angiopoietin 1, angiopoietin 2, angiopoietin 3, angiopoietin 4, angiopoietin 5, angiopoietin 6, angiopoietin 7, angiopoietin-like 1, angiopoietin-like 2, angiopoietin-like 3, angiopoietin-like 4, angiopoietin-like 5, angiopoietin-like 6, and angiopoietin-like 7; wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer, c
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: February 26, 2019
    Inventors: Pui-Kwong Chan, May Sung Mak, Yun Wang
  • Patent number: 10213421
    Abstract: The present invention relates to pharmaceutical compositions containing one or more compounds of formula 1 wherein R1 is H, C1-6-alkyl, C0-4-alkyl-C3-6-cycloalkyl, C1-6-haloalkyl; R2 is H, C1-6-alkyl; X is an anion selected from the group consisting of chloride or ½ dibenzoyltartrate j is 1 or 2. processes for the preparation thereof, and their use to treat diseases connected with the CCR3 receptor.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: February 26, 2019
    Assignee: Alkahest, Inc.
    Inventors: Alfred Fetscher, Jochen Matthias Scher
  • Patent number: 10183154
    Abstract: Various embodiments disclosed herein relate to an implantable device, systems, and methods related thereto, that includes at least one sensor and/or therapeutic agent delivery depot. In one embodiment, the system and device include means for detecting general or specific biological agents in a subject's intestinal tract, and utilizing the information from the detection for determining the timing and content of any therapeutic treatment needed by the subject.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: January 22, 2019
    Assignee: ELWHA LLC
    Inventors: Roderick A. Hyde, Tony S. Pan, Dennis J. Rivet
  • Patent number: 10182995
    Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: January 22, 2019
    Assignee: IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.
    Inventors: David Lickrish, Feng Zhang
  • Patent number: 10179108
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) and other CNS stimulant responsive conditions include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by an extended release.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: January 15, 2019
    Assignee: IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.
    Inventors: David Lickrish, Feng Zhang
  • Patent number: 10174128
    Abstract: Provided is a method for producing low-substituted hydroxypropyl cellulose with less yellowing. More specifically, the method for producing purified low-substituted hydroxypropyl cellulose includes the steps of: reacting alkali cellulose and an etherifying agent to obtain a reaction mixture; dispersing the reaction mixture in water containing a portion of acetic acid necessary for neutralizing the total amount of the reaction mixture to neutralize a portion of the reaction mixture, and then completely neutralizing with the remaining acetic acid to cause precipitation, to obtain a slurry containing crude low-substituted hydroxypropyl cellulose; disintegrating a solid component in the slurry through a cutter pump, the solid component containing the crude low-substituted hydroxypropyl cellulose, and discharging the slurry containing the disintegrated solid component; washing the discharged slurry with water to obtain a cake of purified low-substituted hydroxypropyl cellulose; and drying the cake.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: January 8, 2019
    Assignee: Shin-Etsu Chemical Co., Ltd.
    Inventors: Akira Kitamura, Atsuhiko Yonemochi, Mitsuo Narita
  • Patent number: 10166219
    Abstract: Formulations and methods of manufacturing formulations for use in colonic evacuation are disclosed herein, in an embodiment, a solid dosage formulation includes an intra-granular fraction intermingled with an extra-granular fraction, wherein the intra-granular fraction includes granules comprising at least one osmotic evacuant agent, at least one antacid, and a first pharmaceutically acceptable excipient component, and wherein the extra-granular fraction includes one or more organic acids, a non-metallic lubricating element, and a second pharmaceutically acceptable excipient component.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: January 1, 2019
    Assignee: Redhill Bipharma Ltd.
    Inventors: Reza Fathi, Patrick Laughlin McLean
  • Patent number: 10159638
    Abstract: Compositions of the invention contain, in a cosmetically acceptable aqueous medium, a) a cationic polyelectrolyte, b) at least one surfactant; and (c) from about 0.01 to about 1.2 weight percent of an anionic polyelectrolyte, where the weight ratio of the anionic polyelectrolyte to the cationic polyelectrolyte is from about 0.05 to about 1.2, and where the composition exhibits a viscosity change that is below a minimum significant-change-threshold (??min) and exhibits no measurable yield stress or increase in yield stress value when compared to a substantially identical composition that does not contain from about 0.01 to about 1.2 weight percent of the anionic polyelectrolyte, at a weight ratio of anionic polyelectrolyte to cationic polyelectrolyte of from about 0.05 to about 1.2.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: December 25, 2018
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Michael J. Fevola, Tobias J. Fuetterer, Matthew A. Lohr
  • Patent number: 10154984
    Abstract: A topical pharmaceutical composition containing diacerein and/or its analogs is provided. Also provided is a method for treating various diseases using this topical pharmaceutical composition.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: December 18, 2018
    Assignee: TWi Biotechnology, Inc.
    Inventors: Chih-Kuang Chen, Jing-Yi Lee, Wei-Shu Lu, Carl Oscar Brown, III
  • Patent number: 10143657
    Abstract: The present invention relates to a composition, in particular a solid pharmaceutical composition comprising a compound having the formula I, as a free base or a salt thereof, and a mixture comprising a vehicle and a non-ionic surfactant in an amount sufficient to achieve solubilization of compound (I); and typically wherein the composition is coated with an enteric coating. Such composition is particularly useful in treatment of cancer.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: December 4, 2018
    Assignee: Oncoral Pharma ApS
    Inventor: Bent Højgaard
  • Patent number: 10143659
    Abstract: Disclosed are a controlled release pharmaceutical composition, comprising a melt-extruded pellet including a water-insoluble ammonium methacrylate copolymer, a polyvinyl acetate, and an active ingredient; and a polymer coating layer including a water-insoluble ammonium methacrylate copolymer formed on the surface of the pellet, and an oral formulation including the pharmaceutical composition.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: December 4, 2018
    Assignee: Samyang Biopharmaceutical Corporation
    Inventors: Sang-Yeob Park, Hye-Jung Lim, Kyung-Hee Kim
  • Patent number: 10130602
    Abstract: The invention relates to the use of L-carnitine, a salt of L-carnitine, a derivative of L-carnitine and/or salt of a derivative of L-carnitine, as well as respective methods and compositions, for reducing or preventing fatigue and/or for improving cognitive function in an animal. The animal is preferably a healthy individual and the use is preferably a non-therapeutic use.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: November 20, 2018
    Assignee: Lonza Ltd.
    Inventors: Adriana Williams, Frauke Warrikoff, Ulla Freitas, Richard Sasse, Kevin Owen
  • Patent number: 10124029
    Abstract: A new use or method of use of a thylakoid extract, for oral route of administration, and a composition comprising the thylakoid extract in adjunction with an acceptable carrier for oral administration. Also described is a method for treating or preventing a disease or disorder involving the formation of reactive oxygen species inflammation in an individual, which comprises the step of orally administering an effective dose of a thylakoid extract. Also described is an oral composition comprising purified thylakoids and a carrier for oral ingestion or oral administration, with the proviso that the carrier does not essentially consist of water, physiological saline or propylene glycol. The thylakoid extract or composition is also provided as a food or a food supplement or as a pellet, or encapsulated granules or powder.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: November 13, 2018
    Assignee: GROUPE SANTÉ DEVONIAN
    Inventors: Marc Purcell, Rejean Drouin
  • Patent number: 10118946
    Abstract: This invention provides novel guanylate cyclase C (GC-C) agonists and their therapeutic use. The agonists may be used either alone or in combination with one or more additional agents.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: November 6, 2018
    Assignee: SYNERGY PHARMACEUTICALS INC.
    Inventor: Kunwar Shailubhai
  • Patent number: 10117837
    Abstract: Provided is a method of preparing a stimuli-responsive multifunctional nanoparticle, including in sequence the steps of: (a) conjugating covalently an active targeting moiety to a hydrophilic polymer to form a targeted polymer, (b) conjugating covalently a redox-responsive moiety to the hydrophilic polymer of the targeted polymer to form a targeted redox-responsive polymer, (c) conjugating covalently a pH-responsive moiety of a drug complex to the redox-responsive moiety of the targeted redox-responsive polymer to form a targeted stimuli-responsive polymer-drug conjugate, wherein the drug complex includes a hydrophobic drug covalently linked to the pH-responsive moiety, and (d) adding the targeted stimuli-responsive polymer-drug conjugate and optionally an imaging agent into an aqueous liquid to allow self-assembly into a stimuli-responsive multifunctional nanoparticle, wherein the hydrophobic drug of the stimuli-responsive multifunctional nanoparticle forms a hydrophobic core, and the imaging agent is incorp
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: November 6, 2018
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventors: Chun-Jui Lin, Tzu-Wei Wang
  • Patent number: 10113166
    Abstract: The present invention relates to antisense oligonucleotides and/or compounds that modulate the expression of and/or function of Filaggrin (FLG), in particular, by targeting natural antisense polynucleotides of Filaggrin (FLG). The invention also relates to the identification of these antisense oligonucleotides and/or compounds and their use in treating diseases and disorders associated with the expression of FLG.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: October 30, 2018
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito
  • Patent number: 10098894
    Abstract: This disclosure relates to transdermal pharmaceutical compositions containing progesterone in combination with one or more solubilizing agents and penetration enhancers, wherein the pharmaceutical compositions are formulated as creams for topical administration. In some embodiments, the transdermal pharmaceutical compositions contain progesterone, a medium-chain oil, and d-limonene. In some embodiments, the transdermal pharmaceutical compositions contain progesterone, a medium-chain oil, a penetration enhancer (e.g., propylene glycol, a fatty acid ester of propylene glycol, a glycol ether), and optionally d-limonene. In certain embodiments, the pharmaceutical compositions further include estradiol. Methods for treating conditions associated with hormone deficiency in a subject are also described.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: October 16, 2018
    Assignee: TherapeuticsMD, Inc.
    Inventors: Julia Amadio, Annette Shadiack, Peter H. R. Persicaner, Richard Winneker, Jason Legassie, Thorsteinn Thorsteinsson, Ajay Ghanta
  • Patent number: 10086031
    Abstract: Disclosed are novel processing methods for green coffee beans that result in novel green coffee bean products, including products that incorporate whole green coffee beans. Methods include selecting whole coffee beans in their fresh green unroasted state with naturally-occurring levels of phytonutrients, sterilizing and drying them, applying iterative grinding processes and stabilization techniques, all while avoiding high temperatures. Whole green coffee bean products created and defined by these methods have unexpectedly been found to increase focus and concentration in users, and are believed useful in the treatment of attention and concentration deficits and related disorders, such as attention deficit (AD), attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), and various related and/or comorbid disorders.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: October 2, 2018
    Inventors: Thomas Vella, Samuel Amen
  • Patent number: 10085916
    Abstract: Methods, systems and apparatuses are provided for producing delivery devices, preferably for oral intake of an agent. In the broadest aspect, the method comprises assembling one or more layers comprising one or more materials with an agent or an agent-releasing formulation to form an intergraded, preferably laminated device; folding said integrated delivery device to form a folded integrated delivery device; and at least partially enclosing said folded delivery device to a form suitable for oral delivery. Preferably, the integrated device comprise a first external layer of a first material; a frame of a second material mounted on the first external layer; an agent-releasing formulation housed within the frame; and a second external layer of the first material mounted on the frame.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: October 2, 2018
    Assignee: INTEC PHARMA LTD.
    Inventors: Moshe Tsabari, Avner Balshey, Erez Yofe, Michael Friedman
  • Patent number: 10071077
    Abstract: The invention involves the use of compounds from the class of aroyl-2H-imidazol-2-ones such as enoximone or a pharmaceutically acceptable salt thereof for modulating the immune system involved in a topic and immune-related disorders. In particular, the invention involves the use of (1,3-dihydro-4-methyl-5-[4-(methylthio)benzoyl]-2H-imidazol-2-on) or a pharmaceutically acceptable salt thereof. The invention also involves a pharmaceutical composition including aroyl-2H-imidazol-2-on or a pharmaceutically acceptable salt thereof in an active quantity for the treatment of a topic and immune-related disorders, by modulating the immune system involved in a topic and immune-related disorders. Preference is especially given to a pharmaceutical composition in a dosage unit of 5, 10 or 20 mg, based on the quantity of the active ingredient.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: September 11, 2018
    Assignee: BREAKTHROUGH MEDICAL RESEARCH B.V.
    Inventor: Jan Beute
  • Patent number: 10064828
    Abstract: The disclosure is directed to drug delivery devices that provide for combinations of extended and pulsed controlled release delivery of active pharmaceutical ingredient(s) APIs. The described drug delivery devices for oral administration of therapeutic compositions can include two or more populations of unit dosage forms including one or more API's in various combinations of pulsed and delayed/extended delivery formulations. The population of unit dosage forms are provided in a variety of different vehicles such as granules, beads, pellets, or tablets and can be contained within a drug delivery device of the present disclosure.
    Type: Grant
    Filed: December 23, 2005
    Date of Patent: September 4, 2018
    Assignee: INTELLIPHARMACEUTICS CORP.
    Inventors: Isa Odidi, Amina Odidi
  • Patent number: 10045993
    Abstract: The present invention relates to a pharmaceutical preparation comprising entecavir as an active ingredient, wherein an antioxidizing agent is added to enhance stability of entecavir, and a method for preparing the same. According to the present invention, the invention has an effect that entecavir can be stably maintained in a pharmaceutical preparation containing a certain amount or more of moisture by adding the antioxidizing agent, thereby a pharmaceutical preparation can be provided as a formulation containing a certain amount or more of moisture, for example, an orally disintegrating film formulation.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: August 14, 2018
    Assignee: CTC BIO, INC.
    Inventors: Hong Ryeol Jeon, Do-Woo Kwon, Bong-Sang Lee, Su-Jun Park, Jiyeong Han, Myeongcheol Kil, Min Seop Kim
  • Patent number: 10045946
    Abstract: A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target PK (pharmacokinetics) profiles is described. The dosage form comprises one or more multicoated drug particles (beads, pellets, mini-/micro-tablets) having a barrier coating and a lag-time coating. Each Timed Pulsatile Release (TPR) bead population exhibits pre-determined lag-time followed by differing release characteristics. The composition and thickness of the barrier coating, composition and thickness of the lag-time coating, ratio of IR beads to one or more TPR bead populations and total dose may be varied depending on the alkalinity, pH-dependent solubility and elimination half-life of the active ingredients to achieve target PK profiles (suitable for a once or twice daily dosing regimen) in patients in need of such medications.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: August 14, 2018
    Assignee: ADARE PHARMACEUTICALS, INC.
    Inventor: Gopi M. Venkatesh
  • Patent number: 10039718
    Abstract: The invention provides a composition comprising, a compound of formula (I): or a pharmaceutically acceptable salt thereof and a plurality of solid carrier particles, as well as methods for using the composition to inhibit the activity of cytochrome P-450.
    Type: Grant
    Filed: May 1, 2009
    Date of Patent: August 7, 2018
    Assignee: Gilead Sciences, Inc.
    Inventors: Joanna M. Koziara, Mark M. Menning, Robert G. Strickley, Richard Yu, Brian P. Kearney, Anita A. Mathias
  • Patent number: 10022377
    Abstract: Disclosed herein are compositions and methods for the treatment of pulmonary hypertension, including pulmonary arterial hypertension. The methods include administering to a patient in need thereof an effective amount of anagrelide or derivative thereof. The compositions include an effective amount of anagrelide or derivative thereof, in some instances combined with one or more additional agents for the treatment of pulmonary hypertension.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: July 17, 2018
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi
  • Patent number: 10010518
    Abstract: Prostacyclin compounds and compositions comprising the same are provided herein. Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear C5-C18 alkyl, branched C5-C18 alkyl, linear C2-C18 alkenyl, branched C3-C18 alkenyl, aryl, aryl-C1-C18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described. The linkage, in one embodiment, is via a carbamate, amide or ester bond. Prostacyclin compounds provided herein can also include at least one hydrogen atom substituted with at least one deuterium atom. Methods for treating pulmonary hypertension (e.g., pulmonary arterial hypertension) and portopulmonary hypertension are also provided.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: July 3, 2018
    Assignee: INSMED INCORPORATED
    Inventors: Vladimir Malinin, Walter Perkins, Franziska Leifer, Donna Konicek, Zhili Li, Adam Plaunt
  • Patent number: 10004692
    Abstract: A composition for manufacture of hard hydroxypropyl methyl cellulose capsules comprising a film forming material of hydroxypropyl methyl cellulose having a methoxy content of 27.0-30.0% (w/w), and a hydroxypropoxy content of 4.0-7.5% and as a 2% weight solution, a viscosity of 3.5-6.0 cPs at 20° C., dipping compositions, process for manufacture of hard hydroxypropyl methyl cellulose capsules according to a dip coating process and hard capsule shells.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: June 26, 2018
    Assignee: Capsugel Belgium NV
    Inventors: Dominique Nicolas Cade, David He Xiongwei
  • Patent number: 9999648
    Abstract: The present disclosure concerns embodiments of a combination and/or composition comprising bacillus, and yucca, quillaja or both. Embodiments of methods of making and using the combination and/or composition also are disclosed herein. In some embodiments, the combination and/or composition may be used to improve feed conversion rates in animals. In some embodiments the animals are avians; in other embodiments, the animals are non-avians. Embodiments of the disclosed combination can comprise a first composition comprising Quillaja saponaria, Yucca schidigera, or both, and Bacillus coagulans. Embodiments of the disclosed composition can comprise Quillaja saponaria, Yucca schidigera, or both, and Bacillus coagulans.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: June 19, 2018
    Assignees: Phibro Animal Health Corporation, Desert King International, LLC
    Inventors: David Calabotta, Wendell Knehans, Derek McLean
  • Patent number: 9999673
    Abstract: The invention provides poly(ethylene glycol)-lipid conjugates for use in drug delivery.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: June 19, 2018
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Kallanthottathil G. Rajeev, Muthiah Manoharan, Muthusamy Jayaraman, Martin Maier, Jayaprakash K. Nair, David Butler
  • Patent number: RE47084
    Abstract: The field of the invention is that of oral pharmaceutical medicinal products or compositions, more particularly of the type of those comprising one or more active principles. The aim of the invention is to provide an improved oral medicinal product that can be administered in one or more daily doses, with modified release of active principle (in particular an active principle), for improving the prophylactic and therapeutic efficacy of such a medicinal product. This aim is achieved by means of the multimicrocapsular oral pharmaceutical form according to the invention in which the release of the AP is controlled by means of a double mechanism of triggering the release: “time triggering” and “pH triggering”. This medicinal product comprises microcapsules with modified release of active principle, each containing a core comprising the active principle and one or more swelling agents, and at least one coating making possible the modified release of the active principle.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: October 16, 2018
    Assignee: FLAMEL IRELAND LIMITED
    Inventors: Catherine Castan, Florence Guimberteau, Remi Meyrueix, Gerard Soula